Lidia Karabon

13PUBLICATIONS
32CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 27, 2025
miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy.

Agata Kosmaczewska, Lidia Ciszak, Anna Andrzejczak

|Jul 13, 2024
Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival.

Anna Andrzejczak, Bartosz Małkiewicz, Krzysztof Tupikowski

|Apr 28, 2023
NGS Sequencing Reveals New UCP1 Gene Variants Potentially Associated with MetS and/or T2DM Risk in the Polish Population-A Preliminary Study.

Anna Andrzejczak, Agata Witkowicz, Dorota Kujawa

|Feb 11, 2023
The Variations' in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis.

Anna Andrzejczak, Krzysztof Tupikowski, Anna Tomkiewicz

|Feb 09, 2023
Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.

Nafeesa Moksud, Marta Wagner, Konrad Pawełczyk

|Nov 27, 2021
BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production.

Lidia Karabon, Anna Andrzejczak, Lidia Ciszak

Pageof 3

Frequent Collaborators

6 joint publications

Anna Andrzejczak

3 joint publications

Lidia Ciszak

3 joint publications

Jacek Roliński

3 joint publications

Agata Kosmaczewska